This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of Telaprevir in Subjects With Hepatic Impairment

This study has been completed.
Information provided by:
Vertex Pharmaceuticals Incorporated Identifier:
First received: July 30, 2007
Last updated: October 28, 2008
Last verified: October 2008
The purpose of this study is to assess the safety and pharmacokinetics of Telaprevir following administration of multiple oral doses to subjects with moderate and severe hepatic impairment.

Condition Intervention Phase
Hepatic Insufficiency Drug: telaprevir (VX-950) Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science

Further study details as provided by Vertex Pharmaceuticals Incorporated:

Primary Outcome Measures:
  • Pharmacokinetics

Study Start Date: September 2007
Study Completion Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinically diagnosed with Child Pugh score of 7-9 or greater than 10
  • Women of non-childbearing age

Exclusion Criteria:

  • Tested positive for HIV, Hepatitis C, Hepatitis B
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00509210

United States, Indiana
Indiana University, Department of Medicine,Division of Gastroenterology / Hepatology
Indianapolis, Indiana, United States, 46202
Sponsors and Collaborators
Vertex Pharmaceuticals Incorporated
Principal Investigator: Paul Y Kwo, MD Indiana University, Department of Medicine, Division of Gastroenterology/Hepatology
  More Information Identifier: NCT00509210     History of Changes
Other Study ID Numbers: VX06-950-012
Study First Received: July 30, 2007
Last Updated: October 28, 2008

Keywords provided by Vertex Pharmaceuticals Incorporated:
Liver Disease

Additional relevant MeSH terms:
Hepatic Insufficiency
Liver Diseases
Digestive System Diseases processed this record on August 16, 2017